Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Target Price at $16.38

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.38.

Several research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. Royal Bank of Canada began coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price on the stock. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Donald Notman sold 11,119 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,895 shares of company stock worth $283,772. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of OCUL. GF Fund Management CO. LTD. purchased a new stake in Ocular Therapeutix in the 4th quarter valued at about $28,000. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix during the 4th quarter valued at approximately $43,000. AlphaQuest LLC purchased a new stake in Ocular Therapeutix in the 4th quarter worth about $53,000. GAMMA Investing LLC increased its position in shares of Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 8,112 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 8,446 shares in the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Up 0.4 %

OCUL stock traded up $0.03 during mid-day trading on Friday, hitting $8.33. 73,240 shares of the company were exchanged, compared to its average volume of 1,352,726. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix has a 1-year low of $4.79 and a 1-year high of $11.77. The firm's 50 day simple moving average is $7.32 and its 200 day simple moving average is $8.45. The firm has a market cap of $1.32 billion, a P/E ratio of -6.31 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, sell-side analysts predict that Ocular Therapeutix will post -0.98 EPS for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.